Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of APTIOM (eslicarbazepine acetate) for Partial epilepsies in children younger than four years of age.

Next Previous
Trial Profile

A phase III trial of APTIOM (eslicarbazepine acetate) for Partial epilepsies in children younger than four years of age.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 03 Apr 2023 According to a Sumitomo Pharma media release, the Sumitomo Pharma USA companies (Sumitovant Biopharma, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Sumitomo Pharma America Holdings, Sumitomo Pharma Oncology and Sunovion Pharmaceuticals) combined and named as Sumitomo Pharma America
  • 15 Mar 2017 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top